Key result
Immunosuppressive regimens differentially drive post-transplant cardiovascular and atherosclerosis risk factors.
Answers are grounded in this paper and cite their sources.
Cardiovascular disease is one of the major causes of morbidity and mortality following solid organ transplantation. Many of the current immunosuppressive drugs are associated with an increase of one or more risk factors for the development of atherosclerosis. This review compares the mechanism by which individual immunosuppressive agents may impact on these risk factors and the differential contribution of cyclosporine, tacrolimus, mycophenolate, azathioprine, and Rapamycin to these individual risk factors. Attention to the potential cardiovascular toxicities of individual immunosuppressive agents may help design strategies for maintenance of immunosuppression tailored to individual patients.
No takes yet. Share an insight, caveat, or question.
Leslie W. Miller (2002) conducted a review in Cardiovascular disease following solid organ transplantation. Immunosuppressive agents (cyclosporine, tacrolimus, mycophenolate, azathioprine, and Rapamycin) was evaluated on Cardiovascular toxicities and atherosclerosis risk factors. Immunosuppressive agents including cyclosporine, tacrolimus, mycophenolate, azathioprine, and Rapamycin differentially contribute to cardiovascular risk factors after solid organ transplantation.
Synapse has enriched 10 related papers. Consider them for comparative context: